C.difficile vaccine
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridioides Difficile Associated Disease
Conditions
Clostridioides Difficile Associated Disease
Trial Timeline
Dec 10, 2025 → Jun 7, 2029
NCT ID
NCT07282665About C.difficile vaccine
C.difficile vaccine is a phase 3 stage product being developed by Pfizer for Clostridioides Difficile Associated Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07282665. Target conditions include Clostridioides Difficile Associated Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07282665 | Phase 3 | Recruiting |
Competing Products
7 competing products in Clostridioides Difficile Associated Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD5148 | AstraZeneca | Phase 2 | 52 |
| AZD5148 + Placebo | AstraZeneca | Phase 1 | 33 |
| Ridinilazole + Vancomycin | Summit Therapeutics | Phase 3 | 74 |
| Ridinilazole + Vancomycin | Summit Therapeutics | Phase 3 | 74 |
| REC-3964 | Recursion Pharmaceuticals | Phase 2 | 47 |
| SER-109 | Seres Therapeutics | Pre-clinical | 15 |
| SER-109 | Seres Therapeutics | Phase 3 | 69 |